Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias

British Journal of Haematology

Volumn 130, Issue 5, 2005, Pages 716-725

  Tabellini, Giovanna ^b   Tazzari, Pier Luigi ^c   Bortul, Roberta ^d   Evangelisti, Camilla ^a   Billi, Anna Maria ^a   Grafone, Tiziana ^a   Martinelli, Giovanni ^a   Baccarani, Michele ^a   Martelli, Alberto M ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e CNR   (Italy)

Author keywords

Apoptosis; Leukaemia; Protein phoshorylation; Signal transduction

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARSENIC TRIOXIDE; COMPLEMENTARY DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; WORTMANNIN; ORGANOARSENIC DERIVATIVE; OXIDE;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER RESISTANCE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; LYMPHOCYTE CLONE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; UPREGULATION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; LEUKEMIA; METHODOLOGY; NICK END LABELING; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; JURKAT CELLS; LEUKEMIA; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKEMIA, T-CELL; OXIDES; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 27244456502     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05679.x     Document Type: Article

References (44)

1. Bazarbachi A. Ghez D. Lepelletier Y. Nasr R. de The H. El-Sabban M.E. Hermine O. ( 2004) New therapeutic approaches for adult T-cell leukaemia. Lancet Oncology, 5, 664 672.
2. Bortul R. Tazzari P.L. Billi A.M. Tabellini G. Mantovani I. Cappellini A. Grafone T. Martinelli G. Conte R. Martelli A.M. ( 2005) Deguelin, a PI3K/Akt inhibitor, enhances chemosensitivity of leukemia cells with an active PI3K/Akt pathway. British Journal of Haematology, 129, 677 686.
3. Brazil D.P. Yang Z.Z. Hemmings B.A. ( 2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends in Biochemical Sciences, 29, 233 242.
4. Caplen N.J. Parrish S. Imani F. Fire A. Morgan R.A. ( 2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proceedings of the National Academy of Sciences of the United States of America, 98, 9742 9747.
5. Cappellini A. Tabellini G. Zweyer M. Bortul R. Tazzari P.L. Billi A.M. Falà F. Cocco L. Martelli A.M. ( 2003) The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia, 17, 2157 2167.
6. Choi Y.J. Park J.W. Suh S.I. Mun K.C. Bae J.H. Song D.K. Kim S.P. Kwon T.K. ( 2002) Arsenic trioxide-induced apoptosis in U937 cells involves generation of reactive oxygen species and inhibition of Akt. International Journal of Oncology, 21, 603 610.
7. Cross T.G. Scheel-Toellner D. Henriquez N.V. Deacon E. Salmon M. Lord J.M. ( 2000) Serine/threonine protein kinases and apoptosis. Experimental Cell Research, 256, 34 41.
8. Douer D. Tallman M.S. ( 2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Journal of Clinical Oncology, 23, 2396 2410.
9. Elbashir S.M. Harborth J. Lendeckel W. Yalcin A. Weber K. Tuschl T. ( 2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494 498.
10. Evens A.M. Tallman M.S. Gartenhaus R.B. ( 2004) The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leukemia Research, 28, 891 900.
11. Gao F. Yi J. Yuan J.Q. Shi G.Y. Tang X.M. ( 2004) The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Research, 14, 81 85.
12. Gianni M. Koken M.H. Chelbi-Alix M.K. Benoit G. Lanotte M. Chen Z. de The H. ( 1998) Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood, 91, 4300 4310.
13. Hanada M. Feng J. Hemmings B.A. ( 2004) Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochimica et Biophysica Acta, 1697, 3 16.
14. Hu X.M. Hirano T. Oka K. ( 2003) Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemotherapy and Pharmacology, 51, 119 126.
15. Huan S.Y. Yang C.H. Chen Y.C. ( 2000) Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leukemia and Lymphoma, 38, 283 293.
16. Kondapaka S.B. Singh S.S. Dasmahapatra G.P. Sausville E.A. Roy K.K. ( 2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Molecular Cancer Therapeutics, 2, 1093 1103.
17. Li X. Traganos F. Melamed M.R. Darzynkiewicz Z. ( 1995) Single-step procedure for labeling DNA strand breaks with fluorescein- or BODIPY-conjugated deoxynucleotides: detection of apoptosis and bromodeoxyuridine incorporation. Cytometry, 20, 172 180.
18. Lunghi P. Tabilio A. Dall'Aglio P.P. Ridolo E. Carlo-Stella C. Pelicci P.G. Bonati A. ( 2003) Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia, 17, 1783 1793.
19. Lunghi P. Tabilio A. Lo-Coco F. Pelicci P.G. Bonati A. ( 2005) Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia, 19, 234 244.
20. Martelli A.M. Tabellini G. Bortul R. Tazzari P.L. Cappellini A. Billi A.M. Cocco L. ( 2005) Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histology and Histopathology, 20, 239 252.
21. Milella M. Kornblau S.M. Estrov Z. Carter B.Z. Lapillonne H. Harris D. Konopleva M. Zhao S. Estey E. Andreeff M. ( 2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. Journal of Clinical Investigation, 108, 851 859.
22. Miller Jr., W.H. Schipper H.M. Lee J.S. Singer J. Waxman S. ( 2002) Mechanisms of action of arsenic trioxide. Cancer Research, 62, 3893 3903.
23. Neri L.M. Borgatti P. Tazzari P.L. Bortul R. Cappellini A. Tabellini G. Bellacosa A. Capitani S. Martelli A.M. ( 2003) The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Molecular Cancer Research, 1, 234 246.
24. Perkins C. Kim C.N. Fang G. Bhalla K.N. ( 2000) Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood, 95, 1014 1022.
25. Platanias L.C. ( 2003) Map kinase signaling pathways and hematologic malignancies. Blood, 101, 4667 4679.
26. Puccetti E. Ruthardt M. ( 2004) Acute promyelocytic leukemia: PML/RAR and the leukemic stem cell. Leukemia, 18, 1169 1175.
27. Ramos A.M. Fernandez C. Amran D. Sancho P. de Blas E. Aller P. ( 2005) Pharmacological inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood, 105, 4013 4020.
28. Recher C. Chopin M. Raffoux E. Pierron G. Poupon J. Sigaux F. Dombret H. Stern M.H. ( 2002) In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. British Journal of Haematology, 117, 343 350.
29. 3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. British Journal of Haematology, 116, 555 563.
30. Ryther R.C. Flynt A.S. Phillips III., J.A. Patton J.G. ( 2005) siRNA therapeutics: big potential from small RNAs. Gene Therapy, 12, 5 11.
31. Soignet S.L. Frankel S.R. Douer D. Tallman M.S. Kantarjian H. Calleja E. Stone R.M. Kalaycio M. Scheinberg D.A. Steinherz P. Sievers E.L. Coutre S. Dahlberg S. Ellison R. Warrell Jr., R.P. ( 2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852 3860.
32. Tabellini G. Cappellini A. Tazzari P.L. Falà F. Billi A.M. Manzoli L. Cocco L. Martelli A.M. ( 2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. Journal of Cellular Physiology, 202, 623 634.
33. Tazzari P.L. Cappellini A. Grafone T. Mantovani I. Ricci F. Billi A.M. Ottaviani E. Conte R. Martinelli G. Martelli A.M. ( 2004) Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. British Journal of Haematology, 126, 675 681.
34. Thøger-Andersen A.-S. Junker S. ( 1994) Simple and efficient recovery of rare living lymphoid cells from a vast majority of dead cells. Nucleic Acids Research, 22, 5769 5770.
35. Uddin S. Hussain A. Al-Hussein K. Platanias L.C. Bhatia K.G. ( 2004) Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochemical and Biophysical Research Communications, 320, 932 938.
36. Van Ummersen L. Binger K. Volkman J. Marnocha R. Tutsch K. Kolesar J. Arzoomanian R. Alberti D. Wilding G. ( 2005) A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clinical Cancer Research, 10, 7450 7456.
37. Vermes I. Haanen C. Steffens-Nakken H. Reutelingsperger C. ( 1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods, 184, 39 51.
38. Wada T. Penninger J.M. ( 2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 23, 2838 2849.
39. West K.A. Castillo S.S. Dennis P.A. ( 2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates, 5, 234 248.
40. Woessmann W. Damm-Welk C. Fuchs U. Borkhardt A. ( 2003) RNA interference: new mechanisms for targeted treatment? Reviews in Clinical and Experimental Hematology, 7, 270 291.
41. Xu Z. Stokoe D. Kane L.P. Weiss A. ( 2002) The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth and Differentiation, 13, 285 296.
42. Xu Q. Simpson S.E. Scialla T.J. Bagg A. Carroll M. ( 2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 102, 972 980.
43. Zhao S. Konopleva M. Cabreira-Hansen M. Xie Z. Hu W. Milella M. Estrov Z. Mills G.B. Andreeff M. ( 2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia, 18, 267 275.
44. Zhu J. Chen Z. Lallemand-Breitenbach V. de The H. ( 2002) How acute promyelocytic leukaemia revived arsenic. Nature Reviews on Cancer, 2, 705 713.